Acupuncture Therapy ; Humans ; Medicine, Chinese Traditional ; Moxibustion ; Osteoporosis ; diagnosis ; pathology ; therapy ; Practice Guidelines as Topic

OBJECTIVETo study diagnosis and therapeutic efficacy of transient oeteoporods of the hip (TOH).

METHODSFrom January 2005 to February 2010, 5 patients with TOH were treated with traditional methods. All the patients were male, with an average age of 38.6 years (ranged, 27 to 46 years). The clinical manifestation, physical examination and imageology characteristic was investigated. The therapeutic efficacy was evaluated by Harris hip score.

RESULTSAll the patients were followed up, the duration ranged from 12 to 36 months (averaged, 24 months). The Harris hip score before treatment were 63.1, 86.0, 74.9, 63.6 and 64.8 respectively, while after 6 months treatment, the scores improved to 90.5, 94.5, 89.7, 93.9 and 87.8 respectively. Moreover, 6 months later, the abnormal signal disappeared in MR imaging and X-ray.

CONCLUSIONTransient osteoporosis of the hip is a self-resolving condition and a self-limited disease, the expectant treatment is useful for it.

Adult ; Female ; Hip Joint ; Humans ; Magnetic Resonance Imaging ; Male ; Middle Aged ; Osteoporosis ; diagnosis ; therapy ; Retrospective Studies

PURPOSE: This study was to identify the influencing factors of the compliance level to a therapeutic regimen after a bone mineral densitometry test. METHOD: The sample for the study was 95 people who took the bone mineral densitometry test from March, 2002 to July, 2002. Data was collected by mail using aself reporting questionnaire on the selected variables such as the compliance level, self efficacy, health locus of control, susceptibility, severity, usefulness, barrier, and self esteem. RESULT: The average compliance level was 63.93. Through multiple regression, three independent variables including chance health locus of control on personality, the result of bone mineral density and self-efficacy were entered in the model as the significant determinants of the compliance level after a bone mineral densitometry test. The coefficients of determination of each variable were 10.9%, 8.3% and 8.1% respectively. CONCLUSION: The identification of the determinants of the compliance level to the therapeutic regimen after bone mineral densitometry is expected to contribute to the development of an intervention program to improve the compliance level to the therapeutic regimen in osteoporosis patients.
Aged ; *Bone Density ; Female ; Humans ; Male ; Middle Aged ; Osteoporosis/diagnosis/*therapy ; *Patient Compliance

BACKGROUND: The purpose of this study was to evaluate whether physicians' practice was adequate for the diagnosis and treatment of osteoporosis in patients with proximal humeral fracture over the age of 50 years, which is one of major osteoporotic fractures. METHODS: A retrospective nation-wide cohort study was performed using data collected in 2010 by the Korean Health Insurance Review Agency. The incidences of fractures around the hip, spine, and proximal humerus in patients more than 50 years of age, the frequencies of diagnostic bone density scan for osteoporosis, and the prescription for the osteoporosis medication were analyzed and compared. RESULTS: A search of database identified 48,351 hip fractures, 141,208 spine fractures, and 11,609 proximal humeral fractures in patients more than 50 years of age in 2010. Among these patients, 12,097 (25.0%) of hip fractures, 41,962 (29.7%) of spine fractures, and 1,458 (12.6%) of proximal humeral fractures underwent diagnostic bone density scan (p < 0.001); 4,773 (9.9%) of hip fractures, 27,261 (19.3%) of spine fractures, and 639 (5.5%) of proximal humeral fractures were managed with at least one medication approved for the treatment of osteoporosis (p < 0.001). Furthermore, 1,217 (2.5%) of hip fractures, 7,271 (5.2%) of spine fractures, and 188 (1.6%) of proximal humeral fractures received diagnostic bone density scans as well as osteoporosis medications (p < 0.001). Younger patients (50–69 years of age) were less likely to be evaluated and managed for osteoporosis relative to older patients (≥ 70 years of age) (p < 0.001); and men were less likely to be evaluated and managed for osteoporosis relative to women (p < 0.001). CONCLUSIONS: Current physicians' practice pattern may be inadequate for the diagnosis and treatment of osteoporosis in patients of proximal humeral fractures over the age of 50 years. Additional study and educational programs are necessary to improve this care gap, beginning with physicians who are responsible for the fracture treatment and shoulder diseases.
Aged ; Bone Density ; Bone Density Conservation Agents/therapeutic use ; Female ; Humans ; Male ; Middle Aged ; *Osteoporosis/complications/diagnosis/drug therapy/epidemiology ; Retrospective Studies ; Shoulder Fractures/*complications/*epidemiology

PADAM is defined by International Society for the Study of the Aging Male(ISSAM) as a biochemical syndrome associated with advancing age and characterized by a deficiency in serum androgen with or without decreased tissue sensitivity to androgen. The precise role of androgens in the aging process of men remains unclear, and there have been few controlled clinical studies in aging men to investigate the effects of androgen replacement therapy on various organs and human functions known to deteriorate with age(except for studies on muscle and bone). These organs and functions include the mind, the cardiovascular system, the immune system, and the composition of body fat. In addition, the effect of androgen replacement therapy on the prostate is very important in terms of its safety in aging men. Good randomized, double-blind, placebo-controlled clinical studies in the aging male are clearly lacking. We need studies that can help us better understand the effect of long-term androgen replacement therapy(both with testosterone and DHEA) on important aspects of men's health: cardiovascular disease, body composition, cognition and dementia, osteoporosis, and the prostate. Until such data will become available(probably not for the next decade), we recommend a careful and individualized evaluation of present health problems combined with assessment of prostatic health(rectal examination, transrectal ultrasound, and PSA measurement), cardiovascular health, and cerebral status(including overall quality of life) be undertaken before androgen replacement is initiated. Treatment should be monitored by the same criteria. The future will probably bring the development of 'designer androgens' with(ideally) beneficial effects on the cardiovascular system, bone, muscle, fat tissues, and brain, and simultaneous neutral or even inhibitory effects on the prostate. The onset of PADAM is unpredictable and its manifestations are subtle and variable, which has led to a paucity of interest in its diagnosis and treatment. Urological practice commonly includes a large proportion of men older than 50 years. Therefore, it is important for urologists to recognize the manifestations of PADAM and be familiar with evaluations necessary to document, monitor, and treat it.
Adipose Tissue ; Aging* ; Androgens ; Body Composition ; Brain ; Cardiovascular Diseases ; Cardiovascular System ; Cognition ; Dementia ; Diagnosis ; Hormone Replacement Therapy* ; Humans ; Immune System ; Male ; Men's Health ; Osteoporosis ; Prostate ; Testosterone ; Ultrasonography

Animals ; Bone Density ; Diagnosis, Differential ; Drugs, Chinese Herbal ; pharmacology ; therapeutic use ; Medicine, Chinese Traditional ; Osteoporosis ; drug therapy ; etiology ; metabolism ; Ovariectomy ; Phytotherapy

Aged ; Diagnosis, Differential ; Drugs, Chinese Herbal ; therapeutic use ; Female ; Humans ; Medicine, Chinese Traditional ; Memory ; drug effects ; Menopause ; drug effects ; Middle Aged ; Osteoporosis, Postmenopausal ; drug therapy ; Phytotherapy

Aged ; Bone Density Conservation Agents ; adverse effects ; Female ; Humans ; Organometallic Compounds ; adverse effects ; Osteoporosis, Postmenopausal ; drug therapy ; Stevens-Johnson Syndrome ; chemically induced ; diagnosis ; physiopathology ; Thiophenes ; adverse effects

OBJECTIVETo investigate the net "per case" direct economic burden of osteoporotic hip fracture of in-patients at Peking Union Medical College Hospital (PUMCH), and to explore the related factors which will influence the burden of the disease.

METHODSData was from a retrospective questionnaire on 90 osteoporotic hip fracture in-patients of PUMCH above 50 years old from 1998 to 2002. The direct cost of fracture consisted of inpatient care, outpatient care, home care, appliance, and nutrition etc. Multiple statistics method was used to analyze the factors affecting the direct costs of disease.

RESULTSThe average age of the studied population was 71.78 +/- 9.7 years, including 29 males and 61 females. Yearly direct economic burden for one patient of osteoporotic hip fracture was 32 776 RMB, in which hospitalization expense was 23 107 RMB, accounting for 70.5%. Factors which influencing total direct costs would include: length of hospitalization, occupation and the outcome of disease, while types of hip fracture,occupation and the length of hospitalization affecting the cost during hospitalization. The outcome of disease, length of hospitalization and rehabilitation influenced the cost during convalescence while age, type of payment and treatment, did not show significant influence on the cost of hip fracture.

CONCLUSIONOsteoporosis had become a serious public health problem among the elderly, bringing about the increase of economic burden all over the world both on social healthcare and families of the patients. Our data provided base for preventive health care or health insurance on osteoporosis.

Adult ; Age of Onset ; Aged ; Analysis of Variance ; Cost of Illness ; Female ; Health Knowledge, Attitudes, Practice ; Hip Fractures ; complications ; diagnosis ; economics ; therapy ; Hospitalization ; economics ; Humans ; Logistic Models ; Male ; Middle Aged ; Osteoporosis ; complications ; diagnosis ; economics ; therapy ; Prognosis ; Retrospective Studies

AIMTo evaluate the effect of androgen deprivation therapy (ADT) on bone mineral density (BMD) in prostate cancer patients.

METHODSForty-nine prostate cancer patients with their BMD determined were divided into two groups: the non-treated group included 21 patients before the commencement of ADT and the treated group, 28 patients, who had received ADT for more than 1 year. BMD was measured by dual energy X-ray absorptiometry (DEXA) in the lumbar spine (L2-4) and femoral neck.

RESULTSThirteen (62 %) non-treated and 23 (82 %) treated patients fulfilled the BMD criteria for osteopenia or osteoporosis. Z scores for age-matched control in lumbar spine and femoral neck were -0.9 +/- 0.7 and -0.6 +/- 0.5, respectively, in the treated group, and -1.8 +/- 1.1 and -1.6 +/- 1.0, respectively, in the non-treated group, the differences between the two groups were highly significant (P<0.01).

CONCLUSIONProstate cancer patients who received ADT for more than 1 year had a significantly lower BMD in the lumbar spine and femoral neck than those before the beginning of ADT.

Absorptiometry, Photon ; Aged ; Aged, 80 and over ; Androgens ; deficiency ; Bone Density ; Bone Diseases, Metabolic ; diagnosis ; etiology ; Gonadotropin-Releasing Hormone ; therapeutic use ; Humans ; Male ; Orchiectomy ; adverse effects ; Osteoporosis ; diagnosis ; etiology ; Prostatic Neoplasms ; therapy